Clinical Trial Update: The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Fruquintinib, Tislelizumab, and stereotactic ablative radiotherapy in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN